Understanding a breast cancer diagnosis within hours, not weeks.

That's Visible Intelligence.

Learn More About PreciseBreast

Our Solution

Redefining the standard of cancer care

PreciseBreast^TM uses visual AI-analysis of tissue samples already collected to objectively classify breast cancer patients into two cohorts of low and high risk of tumor recurrence. Taking only two days from slide submission to report generation, PreciseBreast powers faster, data-informed decision making between patients and their oncology care team and complements both pathologist’s tumor grading and gene expression testing.

Learn More About PreciseBreast

The Underlying Problem

Tumor analysis is not accurate enough for many patients

Current standards of care in oncology can be subjective, leading to a high percentage of tumors receiving intermediate grading. As a result, many patients are forced to anxiously await the results of gene expression testing for over a month, delaying vital decisions regarding their care plan.

50%

of breast tumors are categorized as Grade 2*

65%

Intra-observer variations in grading results***

56%

of Grade 3 tumors are low risk**

22%

of Grade 2 tumors are high risk**

78%

of Grade 2 tumors are low risk**

1 in 8 women will be diagnosed with breast cancer in their lifetime.

*Sparano, New England Journal of Medicine. 2018
**Based on a retrospective longitudinal study of more than 2,000 cancer cases. Fernandez, G., Prastawa, M., Madduri, A.S. et al. Breast Cancer Research 2022’.
***Paik, New England Journal of Medicine, 2004

The current standard

Gene expression testing has its limitations

While gene expression testing adds significantly to the information provided by tumor grading, it can take up to six weeks to complete and costs more than $4,000. And because it’s used primarily with excisional specimens, it requires significant time and labor of the pathology department. Even then, gene expression testing may still rely on subjective tumor grading in its risk score, and the limited reporting features can lead to clinical ambiguity.

Our Solution

Making Risk Clearly Visible

Our study of more than 2,000 breast cancer cases* identified 7 morphologic factors that can be visualized in pathology slides and 4 clinical features which, combined in our proprietary algorithm, best predict recurrence at 6 years. Together, the Morphology Feature Array® produces a single Risk Score between 0 and 100 that accurately and consistently stratifies patients into cohorts of low and high risk of tumor recurrence.

The results

Spread the news fast

PreciseBreast provides objective and reliable risk stratification in ~48 hours, allowing oncologists to confidently discuss results - in days, rather than weeks - to relieve patient anxiety and to allow for a more comprehensive shared decision making process.